BRIGHT MINDS BIOSCIENCES INC.
Close on Oct 19, 2026
About Bright Minds Biosciences
Pharmaceutical Preparations, SIC 2834
Bright Minds Biosciences Inc. operates as a Canadian biotechnology and pharmaceutical company classified under pharmaceutical preparations. The provided text indicates that the enterprise conducts its activities alongside wholly owned subsidiaries. However, specific operational segments, proprietary therapeutic products or clinical pipeline assets, distinct commercial services, and identified customer groups are not detailed within the excerpted filing text. The entity focuses on administrative, governance, and regulatory compliance functions necessary for maintaining public reporting requirements across relevant capital oversight frameworks.
In terms of geographic footprint and scale, the business maintains dual corporate headquarters situated in North America. Its Canadian corporate headquarters is located in Vancouver, British Columbia, representing the jurisdiction where the organization is incorporated. Additionally, the company operates a United States corporate headquarters based in Chicago, Illinois, while also designating an agent for service in New York, New York. Further details concerning workforce size, laboratory facilities, or broader operational locations are not specified.
Summary of the business section of Bright Minds Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BRIGHT MINDS BIOSCIENCES INC.
- Headquarters
- Chicago, IL
- Address
- 400 N Aberdeen St Suite 900 60642
- Phone
- (647) 407-2515
- Website
- brightmindsbio.com
- Employees
- 1, Sep 30, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- September 30
- Auditor
- De Visser Gray LLP, Vancouver, Canada
Stock & identifiers
- Ticker
- DRUG
- Exchange
- Nasdaq
- IPO date
- Mar 22, 2021
- Shares outstanding
- 8M, Sep 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-5 reverse, Dec 29, 2023; 1-for-5 reverse, Jul 14, 2023
- SEC CIK
- 1827401
- CUSIP
- 10919W405
- ISIN
- US10919W4050
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Bright Minds Biosciences's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“However, the Company's wholly-owned subsidiary, Bright Minds Biosciences LLC, has one employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 2, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |